Insider Buying: Mobia Medical (NASDAQ:MOBI) Director Purchases 16,441 Shares of Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 16,441 shares of Mobia Medical stock in a transaction on Tuesday, August 18th. The stock was acquired at an average price of $12.07 per share, for a total transaction of $198,442.87. Following the purchase, the director owned 318,332 shares of the company’s stock, valued at approximately $3,842,267.24. This trade represents a 5.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mobia Medical Price Performance

Shares of NASDAQ:MOBI traded down $0.47 on Thursday, hitting $10.95. 71,930 shares of the company’s stock were exchanged, compared to its average volume of 103,512. Mobia Medical, Inc. has a 12 month low of $10.19 and a 12 month high of $15.29. The company has a market capitalization of $364.53 million and a PE ratio of -0.57. The stock’s 50 day simple moving average is $12.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI) last issued its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The business’s revenue was up 102.4% compared to the same quarter last year. Equities analysts forecast that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wolfe Research started coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They issued an “outperform” rating for the company. JPMorgan Chase & Co. raised their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Weiss Ratings assumed coverage on Mobia Medical in a report on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Finally, Bank of America began coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.